Clinical Trial Update: A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria [Phase 3]

View source ↗

Summary

Phase 3 trial updating results for SB12 (eculizumab biosimilar) compared to Soliris in paroxysmal nocturnal hemoglobinuria (PNH) has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• SB12 (Proposed Eculizumab Biosimilar) (eculizumab biosimilar)
• SOLIRIS (eculizumab)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED | Results posted: 2024-03-26